Translational & Clinical Research – Pharmacological
Drug Development - Existing Targets
- Milestone 5.A •
Initiate first in human, phase I drug trials for therapeutic agents against at least 6 existing therapeutic targets…
- Milestone 5.B •
Initiate phase II (proof of concept) drug trials for agents against 3-6 currently known therapeutic targets…
- Milestone 5.C •
Initiate phase III drug trials for agents against at least 3 currently known therapeutic targets…
- Milestone 5.D •
Prepare for and initiate clinical trials that aim to alleviate or slow the course of LBD symptoms, and delay or prevent the onset of disease.
- Milestone 5.E •
Develop disease-modifying interventions for LBD based on discovering biomarkers, molecular targets, and genetic and environmental modifiers that enhance, delay or prevent the onset of disease.
Drug Development - Novel Targets
- Milestone 6.A •
Establish a searchable, open access research database that contains all clinical, biomarker, and epidemiological data, and related genotypes and phenotypes from existing genetic studies…
- Milestone 6.B •
Establish a consortium of genetics and genomics experts to develop and execute a large scale sequencing project to analyze the genomes of a large number of well characterized individuals…
- Milestone 6.C •
Identify, characterize, and complete early validation for at least 6 novel therapeutic targets for AD and AD-related dementias…
- Milestone 6.D •
Initiate drug discovery efforts to develop novel therapeutic agents against at least 6 novel therapeutic targets...
- Milestone 6.E •
Initiate first in human, phase I drug trials for therapeutic agents against at least 6 novel therapeutic targets...
- Milestone 6.F •
Initiate phase ll (proof of concept) drug trials for agents against 3-6 novel therapeutic targets...
- Milestone 6.G •
Initiate Phase III drug trials for agents against at least 3 novel therapeutic targets...
- Milestone 6.H •
Initiate interdisciplinary research programs that integrate clinical, genomic and mechanistic research...
- Milestone 6.I •
Expand efforts to genotype patients with FTD and identify new genes and their functional relationship to FTLD pathogenesis.
Drug Repurposing and Combination Therapy Development
- Milestone 7.A •
Expand existing and develop new systems biology and systems pharmacology research programs...
- Milestone 7.B •
Initiate research programs for translational bioinformatics and network pharmacology...
- Milestone 7.C •
Continue to develop resources, capabilities and partnerships to advance data-driven drug repositioning and combination therapy...
- Milestone 7.D •
Initiate early clinical development for at least 6 existing drugs or drug combinations for the treatment or prevention of AD and AD-related dementias.
- Milestone 7.E •
Initiate at least 3 phase III trials with repurposed drugs or drug combinations...